Two Cheap Drugs Extended Mouse Lifespan by 70%. But Only If You're Male.

Two existing, inexpensive drugs just extended the remaining lifespan of elderly male mice by 73%. The mice were 25 months old — the rodent equivalent of 75-year-old humans. They weren't genetically engineered. They were frail.

The catch: it didn't work in females at all.

The Combo Nobody Expected

The study came out of UC Berkeley, led by Irina Conboy, one of the most respected names in aging biology. Her team published the results in Aging-US in late 2025. It became the journal's cover article. Outside longevity research circles, almost nobody noticed.

The two drugs: oxytocin and an Alk5 inhibitor.

Oxytocin is the hormone most people associate with love and childbirth. It's FDA-approved. It costs almost nothing. Your body already makes it, just less of it as you age.

The Alk5 inhibitor blocks TGF-beta, a signaling pathway that ramps up in older tissue and drives inflammation and cellular damage. Several Alk5 inhibitors are already in Phase II clinical trials for cancer and fibrosis.

Neither drug is new. Neither is exotic. Neither requires gene therapy, stem cells, or billion-dollar infrastructure.

When Conboy's team injected frail 25-month-old male mice with this combination, the results were — by aging research standards — extraordinary.

The Numbers

Treated males lived 73% longer from the point of treatment than untreated controls. That translated to a 14% increase in overall median lifespan. At any given moment, treated males were nearly three times less likely to die than controls.

They didn't just survive longer. They moved better, lasted longer on endurance tests, and scored higher on memory tasks. By standard frailty metrics, they were biologically younger than their birth certificates said.

The treatment also cleaned up their blood. Aging produces what researchers call "biological noise" — erratic patterns in circulating proteins that serve as a recognized marker of deterioration. In treated males, that noise quieted. Their protein signatures looked younger.

The Sex Gap Nobody Can Explain

Here's where it gets uncomfortable for longevity science: female mice got almost nothing.

Both sexes showed short-term improvements. But after four months of continuous treatment, only males maintained the gains. Females showed no lifespan extension. No sustained health improvements. Middle-aged females did experience increased fertility — but that was it.

The researchers don't fully understand why. The honest answer is that aging biology differs between sexes in ways science hasn't mapped yet. And most longevity research has historically tested on males, or mixed sexes without separating the data.

This study did what most don't: it tracked males and females separately, reported the failure in females alongside the success in males, and flagged the gap as a critical open question.

That's more transparency than most of the longevity industry offers.

Why This Matters Beyond Mice

Mouse studies fail in humans all the time. That's worth stating clearly. The history of longevity research is littered with compounds that made mice live longer and did nothing for people.

But this result has a few things going for it.

First, the drugs already exist. Oxytocin is in hospitals today. Alk5 inhibitors are in clinical trials. The regulatory path to human testing is shorter than it would be for a novel compound.

Second, the mice were old and frail. Most longevity studies start treatment in young or middle-aged animals. Showing results in the geriatric equivalent of 75-year-olds is a higher bar, and the results were stronger for it.

Third, the effect size is enormous. A 73% extension of remaining lifespan isn't an incremental gain. Rapamycin, the current gold standard longevity drug in animal models, typically extends lifespan by 10-25%. Metformin shows modest effects. This combination blew past both.

The Bigger Picture

The longevity field is at an inflection point. Unity Biotechnology just reported encouraging Phase 2b results for senolytic therapies. Klotho — a protein that appears to prevent brain aging — is being fast-tracked into clinical trials at UCSF after injections reversed cognitive decline in old mice. Rapamycin is showing early human evidence for immune enhancement.

What Conboy's work adds isn't just another mouse study. It's a proof of concept that cheap, existing drugs — used in combination, started late in life — can produce results that dwarf anything the field has seen.

The sex difference is a problem, not a footnote. If the mechanism only works in males, that limits half the human population from benefiting. Understanding why is now one of the most important questions in aging research.

What Happens Next

Human trials aren't imminent, but they're plausible. The biggest obstacle isn't regulatory — it's that nobody's sure which Alk5 inhibitor to pair with oxytocin, or at what dose, or for how long. The mouse protocol used subcutaneous injections. A human version would need to figure out delivery, dosing, and safety monitoring.

Conboy's lab at Berkeley is continuing the work. The longevity community is paying attention. The mainstream media, so far, isn't.

A 73% lifespan extension in elderly mice using two cheap drugs should be front-page news. The fact that it only worked in half the population should be too. Both matter. Both are the kind of findings that change a field — if anyone's listening.